Our goal is to realize the full potential of in-line first and last liter products
Estimated % of PDT R&D spend for FY2023
Expanded indications and benefit-risk datasets
60%
Device-driven solutions for diagnosis, management, and long-term follow-up Global expansion New formulations
Optimizing value of in-line products
10%
30%
Plasma production efficiencies
New plasma-derived therapies
43
Immunoglobulins provide the scaffold for PDT innovation
Current State
US & EU IgG use by indication*
PID and other immunology SID
Exploring efficacy and safety of HYQVIA in patients with neuro-immune